Main
METASTATIC COLORECTAL CANCER
Systemic anticancer therapy based on the chemotherapeutic agents 5-fluorouracil (5-FU)/capecitabine, oxaliplatin and irinotecan in combination with epidermal growth factor receptor (EGFR) or vascular endothelial growth factor inhibitors are the cornerstone of the treatment of metastatic colorectal cancer (mCRC)Precision medicine is widely used to select patients for targeted therapies and immunotherapies for mCRC according to the presence or absence of genomic biomarkers. As such, the detection of In this study, given the lack of genomic biomarkers and the limited clinical benefit of FTD/TPI in unselected patients with mCRC, we harnessed the power of whole-genome somatic profiles coupled with patient outcomes to identify biomarkers of response and resistance to FTD/TPI. Key findings were then validated in a real-world cohort of FTD/TPI-treated patients with mCRC (